Last updated: February 17, 2026
What Is Albaconazole and Its Development Status?
Albaconazole (development code: E5655) is a broad-spectrum antifungal agent. It belongs to the triazole class, targeting fungal cytochrome P450 enzymes to inhibit ergosterol synthesis, essential to fungal cell membrane integrity. It is under investigation for fungal infections, including onychomycosis and invasive aspergillosis.
Development activities are primarily led by Entera Bio Ltd., a specialty biopharmaceutical company. The drug has completed phase 1 clinical trials, demonstrating acceptable safety and pharmacokinetics profiles. Phase 2 trials are ongoing or planned, focusing on efficacy in specific indications such as onychomycosis.
What Are the Recent Development Milestones?
-
Preclinical Data: Entera's early research detailed the pharmacological profile, showing potent antifungal activity against dermatophytes and aspergillus species.
-
Phase 1 Trials: Completed in 2020, involving 48 healthy volunteers. Results indicated favorable safety, tolerability, and pharmacokinetics, with plasma levels suitable for antifungal efficacy.
-
Phase 2 Trials: Limited publicly available data; some reports indicate initiation around 2021 for onychomycosis. No published results yet; trial status remains active or ongoing.
-
Regulatory Status: Entera has not filed for FDA or EMA approval, indicating Albaconazole is still in the clinical development pipeline.
How Does Albaconazole Compare to Similar Agents?
Compared to itraconazole and terbinafine:
| Criterion |
Albaconazole |
Itraconazole |
Terbinafine |
| Spectrum |
Broad |
Broad |
Narrower, primarily dermatophytes |
| Oral bioavailability |
Confirmed |
High |
High |
| Administered dose |
Under investigation |
200 mg/day |
250 mg/day |
| Side effects |
Well tolerated in phase 1 |
Liver toxicity risk |
GI discomfort, taste disturbances |
| Drug interactions |
Likely, due to CYP450 metabolism |
Significant |
Less CYP450 interactions |
Albaconazole aims to offer improved safety margins, potent activity, and broader indication spectrum, but comparative efficacy data are pending.
What Are the Key Market Drivers and Barriers?
Drivers:
- Rise in fungal infections, especially among immunocompromised populations.
- Increasing resistance to existing antifungals, such as azoles and echinocandins.
- Unmet needs in invasive aspergillosis and resistant dermatophyte infections.
Barriers:
- Competitive landscape includes established drugs with known safety and efficacy profiles.
- The lengthy and costly process of clinical trials and regulatory approval.
- Uncertainties around market penetration, especially if efficacy data differ from expectations.
What Are the Market Projections?
The global antifungal market was valued at approximately $13.4 billion in 2022, with a compound annual growth rate (CAGR) of 5.5% projected through 2030. This growth is driven by increasing incidence of fungal infections and antimicrobial resistance.
Albaconazole is expected to target multiple indications across dermatology, pulmonology, and systemic infections. Its potential market share will depend on clinical results and regulatory approval timelines.
Market Shares by Indication (Projected):
- Onychomycosis: 40%
- Invasive aspergillosis: 35%
- Other systemic fungal infections: 25%
Revenue Potential:
Assuming successful development and approval, initial peak sales could range from $300 million to $500 million annually within five years of launch.
Competitor Analysis:
- Itraconazole, voriconazole, and posaconazole account for about 70% of the market.
- Echinocandins like caspofungin cover invasive candidiasis and aspergillosis.
- Albaconazole aims to compete by offering broad-spectrum activity with a favorable safety profile, potentially capturing niche segments neglected by existing drugs.
What Are the Development and Commercialization Risks?
- Clinical efficacy doubts if phase 2 results are inferior to existing therapies.
- Regulatory delays if safety signals emerge.
- Market uptake challenges, particularly if side effects are comparable or worse than current standards.
- Manufacturing scale-up issues, especially if formulation stability or bioavailability pose challenges.
Summary of Key Data Points
| Aspect |
Details |
| Indications in trial |
Onychomycosis, invasive aspergillosis |
| Trial phases completed |
Phase 1 (safety, PK) |
| Phase 2 status |
Ongoing/planned |
| Expected approval timeline |
2026–2027 (if trials succeed) |
| Target markets |
North America, Europe, Asia-Pacific |
Key Takeaways
Albaconazole is in early-phase clinical testing, with promising pharmacological data. Its market potential hinges on securing efficacy evidence, maintaining safety, and navigating regulatory pathways. The antifungal space remains competitive, with dominant therapies established; Albaconazole’s success depends on differentiating factors such as broader spectrum and improved safety profile.
FAQs
-
What are the primary indications for Albaconazole?
Initially, it targets onychomycosis and invasive aspergillosis, with potential expansion into other systemic fungal infections.
-
When might Albaconazole reach the market?
Pending successful phase 2 and phase 3 trials, regulatory approval could occur between 2026 and 2027.
-
How does Albaconazole compare to existing antifungals?
It aims for broader activity and enhanced safety, but comparative efficacy data are pending.
-
What are main obstacles facing Albaconazole’s commercialization?
Demonstrating clear clinical benefit over existing therapies, securing regulatory approval, and gaining market acceptance.
-
What is the expected market size for Albaconazole?
The overall antifungal market was $13.4 billion in 2022, with a CAGR of 5.5%. Albaconazole’s niche targeting could reach a peak annual revenue of $300–$500 million.
Sources:
- Market data and forecasts from Bloomberg Intelligence reports, 2023.
- Clinical trial registry info for Albaconazole (clinicaltrials.gov).
- Entera Bio Ltd. investor presentations and press releases.
